Navigation Links
EpiCept Accelerates Development of Phase I Clinical Study for Cancer

EpiCept Corporation today announced that with the initiation of a new study center, Tower Cancer Research Foundation in Los Angeles, it will accelerate the recruitment of patients in the currently ongoing Phase I clinical study of EPC2407, a novel small molecule vascular disruption agent (VDA) and apoptosis inducer for the treatment of patients with advanced solid tumors and lymphomas. The first two cohorts of patients have been completed according to schedule at Scottsdale Healthcare Center. The third cohort is currently ongoing at Scottsdale Healthcare Center and at the University of California, Moores Cancer Center, San Diego.

EPC2407 belongs to a novel class of microtubulin inhibitors discovered by EpiCept. These compounds cause caspase activation, cell cycle arrest, and apoptotic death in cancer cells.

The Phase I trial of EPC2407 is now being conducted in three U.S. cancer centers and will administer increasing doses to small groups in approximately 30-40 patients with advanced stages of solid tumors. The primary objectives of the study are to determine the safety (maximum tolerated dose) and the pharmacokinetic profile of the drug. The study will also characterize the pharmacodynamic effects on tumor blood flow and identify early signs of objective anti-tumor response as measured by CT scans, MRI or PET, in these advanced cancer patients with well vascularized solid tumors.

Dr. Peter J. Rosen, Medical Director at Tower Cancer Research Foundation, stated, "Tower Oncology is very excited to work with EpiCept on the clinical development of EPC2407, a product with a new mechanistic approach, which could offer significant advantages in the fight against cancer."

EpiCept President and Chief Executive Officer Jack Talley commented, "We are pleased to be joined by Tower Cancer Research Foundation in the development of EPC2407 and we believe that their participation will result in our completing the trial ahead of p
'"/>




Page: 1 2

Related medicine news :

1. Developmental, neurologic problems common in extremely preterm infants
2. Development of AIDS vaccine -- Chiron Corp in talks with four Indian cos
3. Missing Protein In Cancer Development
4. Tomatoes Might Inhibit the Development Of Prostate Cancer
5. Pollution Found To Impair Lung Development
6. Treating Depression In Children Could Lead To Poor Bone Development
7. Developmental Origins of Polycystic Ovarian Syndrome
8. Sleep Not Critical For Early Brain Development Of Baby Dolphins
9. ‘Loud Noise’ Research may help in Development of Prosthetics for Eldery
10. Stop Watching TV: Toddler Development Affected
11. Vitamin Supplements During Pregnancy to Boost Fetal Development
Post Your Comments:
(Date:8/29/2015)... ... August 30, 2015 , ... On September 30, 2015, the Career ... the 10 regionally accredited Maricopa Community Colleges , will be hosting a Job ... pursuing employment information and opportunities. , The Expo has expanded to much more than ...
(Date:8/29/2015)... ... August 29, 2015 , ... Targeted therapies, made possible by ... of patients, according to a newly published report. Surviving Mesothelioma has more on ... , The authors of the new paper focus on several types of ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... chronic obstructive pulmonary disease (including emphysema), or asthma, are at higher risk from ... previous heart attack, heart failure or heart-rhythm problems (arrhythmia or irregular heartbeat) are ...
(Date:8/28/2015)... ... 28, 2015 , ... Joining a growing number of hospitals ... management companies to partner with Wound Care Advantage (WCA) to utilize the ... , Transitioning wound care management providers can be a complex undertaking. WCA provides ...
(Date:8/28/2015)... ... August 28, 2015 , ... With the goal of ... for the second year to the Adams County Fairgrounds in Mendon, IL on May ... raise money to support music education in the underfunded school districts of Mendon and ...
Breaking Medicine News(10 mins):Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Top Mesothelioma Researchers Highlight Targeted Therapies in New Report, According to Surviving Mesothelioma 2Health News:Heart Fit Clinic Sounds the Alarm on Forest Fire Smoke and Chronic Heart Disease in Calgary Area 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2
... contain possibly hazardous chemicals called polybrominated diphenyl ethers (PBDEs). ... Standards and Technology and the Environmental Protection Agency of ... yet clear how dangerous these PBDEs are, though some ... structure is strikingly similar to that of PCBs, which ...
... are suffering from mental illness after serving in war-torn ... or longer for treatment// from the National Health Service ... by British Ministry of Defence (MoD) showed 2,123 servicemen ... after returning from Iraq since 2003. More than 320 ...
... has set up a facility in Chennai, the state ... ,Called Poison Control Training and Research Centre, ... It can handle emergency situations like mass poisoning. It ... services and counseling. An intensive care unit, a library, ...
... the hospitals run by NHS trusts, more and more people ... According to the Daily Telegraph, the bed occupancy rates in ... ,Norman Lamb, the health spokesman of the Liberal ... an uphill task to keep patients clean and isolate them. ...
... a tool to help hospitals prepare for disasters ... Electronic Mass Casualty Assessment & Planning Scenarios (EMCAPS) ... as a flu epidemic, bioterrorist attack, flood or ... of victims, wind direction, available medical resources, bacterial ...
... posed by mercury contaminated fish are enormous and especially ... careful about how much// and which fish they eat ... a special issue of the international science journal Ambio. ... Mercury as a Global Pollutant last August in Madison, ...
Cached Medicine News:Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 2Health News:Methylmercury in Marine Fish Pose Health Risks to Pregnant Women and Elderly Men 3
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
(Date:8/28/2015)... 2015 The global mHealth ... billion by 2020, growing at a CAGR of 47.6% ... by Grand View Research, Inc. Monitoring services is expected ... 2014 to 2020.      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ... rising incidences of chronic diseases such as cancer, heart ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation (Nasdaq: ... to present at three upcoming healthcare conferences.  ... CEO, will present at the Rodman & Renshaw Investment ... time. The conference is being held at the St. ... . A live audio webcast of the presentation will ...
Breaking Medicine Technology:Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 2mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 3mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 4mHealth Market is Expected to Reach $49.12 Billion By 2020: Grand View Research, Inc. 5DURECT to Participate in Upcoming Healthcare Conferences 2
... symptoms of SLE,disease at 52 Weeks and ... weeks-, ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ ... presentation of Phase 2,trial data demonstrating that ... clinical,measures, was well tolerated and improved quality ...
... June 13, 2007 /PRNewswire/ -- Two studies presented,today ... at peak,plasma levels, nor did it impair middle-of-the-night ... from chronic,insomnia. The results of the studies were ... Professional Sleep Societies,(APSS). , "These data are important ...
Cached Medicine Technology:Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 2Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 3Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 4Study Demonstrated Rozerem (ramelteon) Does Not Affect,Middle-of-the-Night Balance in Older Adults with Insomnia 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: